Exogenous human beta amyloid peptide interferes osteogenesis through Sox9a in embryonic zebrafish
- PMID: 31264162
- DOI: 10.1007/s11033-019-04948-8
Exogenous human beta amyloid peptide interferes osteogenesis through Sox9a in embryonic zebrafish
Abstract
The two major hallmarks of Alzheimer's disease (AD) are beta-amyloid plaques and neurofibrillary tangles. Amyloid peptide aggregations in the brain cause loss of synaptic connections and subsequent neurotoxicity leading to neurodegeneration and memory deficits. However, the physiological effects of beta-amyloid on early embryonic development still remain unclear. Administration of human beta-amyloid peptide (1-42) through cerebrospinal ventricular injection was carried out at 24 hpf (hours post fertilization) and it was uptaken into the cellular layers of the early ventricular development without any plaque aggregation. Whole-mount Immunostaining of zebrafish embryos injected with the beta-amyloid at 60 hpf revealed the delay in Sox9a expression. Decreased level of cartilage to bone transformation rate in 15 dpf (days post fertilization) zebrafish was observed by differential staining. These results suggest the possible existence of a genetic relationship between extrinsic amyloid peptide and Sox9a expression. Thus, our results demonstrated that the human beta-amyloid influences bone development through Sox9a expression during osteogenesis in zebrafish.
Keywords: Beta-amyloid; Cartilage; Cerebrospinal ventricular injection; Osteogenesis; Sox9a; Zebrafish.
Similar articles
-
Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.Elife. 2020 Mar 31;9:e52589. doi: 10.7554/eLife.52589. Elife. 2020. PMID: 32228858 Free PMC article.
-
A zebrafish sox9 gene required for cartilage morphogenesis.Development. 2002 Nov;129(21):5065-79. doi: 10.1242/dev.129.21.5065. Development. 2002. PMID: 12397114
-
Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.J Alzheimers Dis. 2021;84(4):1391-1414. doi: 10.3233/JAD-215139. J Alzheimers Dis. 2021. PMID: 34719499 Review.
-
Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer's disease.Pathol Int. 2017 Apr;67(4):185-193. doi: 10.1111/pin.12520. Epub 2017 Mar 5. Pathol Int. 2017. PMID: 28261941 Review.
-
Sox9a regulation of ff1a in zebrafish (Danio rerio) suggests an involvement of ff1a in cartilage development.Comp Biochem Physiol A Mol Integr Physiol. 2009 May;153(1):39-43. doi: 10.1016/j.cbpa.2008.10.003. Epub 2008 Oct 12. Comp Biochem Physiol A Mol Integr Physiol. 2009. PMID: 18950725
Cited by
-
Revisiting the Impact of Neurodegenerative Proteins in Epilepsy: Focus on Alpha-Synuclein, Beta-Amyloid, and Tau.Biology (Basel). 2020 Jun 12;9(6):122. doi: 10.3390/biology9060122. Biology (Basel). 2020. PMID: 32545604 Free PMC article. Review.
References
-
- Findeis M (2007) The role of amyloid β peptide 42 in Alzheimer’s disease. Pharmacol Ther 116(2):266–286. https://doi.org/10.1016/j.pharmthera.2007.06.006 - DOI - PubMed
-
- Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J (2014) Amyloid-beta: a crucial factor in Alzheimer’s disease. Med Principles Pract 24(1):1–10. https://doi.org/10.1159/000369101 - DOI
-
- Carpenter M, Crutcher K, Kater S (1993) An analysis of the effects of Alzheimer’s plaques on living neurons. Neurobiol Aging 14(3):207–215. https://doi.org/10.1016/0197-4580(93)90002-s - DOI - PubMed
-
- DeMattos R, Bales K, Cummins D, Dodart J, Paul S, Holtzman D (2001) Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci 98(15):8850–8855. https://doi.org/10.1073/pnas.151261398 - DOI - PubMed - PMC
-
- Mawuenyega K, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris J et al (2010) Decreased clearance of CNS-amyloid in Alzheimer’s disease. Science 330(6012):1774. https://doi.org/10.1126/science.1197623 - DOI - PubMed - PMC